Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators. Kolb M, et al. N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. N Engl J Med. 2018. PMID: 30220235 Clinical Trial.
BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the di …
BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of …
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
Behr J, Kolb M, Song JW, Luppi F, Schinzel B, Stowasser S, Quaresma M, Martinez FJ. Behr J, et al. Am J Respir Crit Care Med. 2019 Dec 15;200(12):1505-1512. doi: 10.1164/rccm.201903-0488OC. Am J Respir Crit Care Med. 2019. PMID: 31365829 Free PMC article. Clinical Trial.
Rationale: In the INSTAGE trial in patients with idiopathic pulmonary fibrosis (IPF) and severely impaired gas exchange, nintedanib plus sildenafil was associated with numerical benefits on St. ...In both subgroups, nintedanib
Rationale: In the INSTAGE trial in patients with idiopathic pulmonary fibrosis (IPF) and severely impaired gas e …
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Richeldi L, et al. BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4. BMC Pulm Med. 2020. PMID: 31914963 Free PMC article.
The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients with IPF and DLco ≤35% predicted. ...Confirmed or suspected idiopathic acute exacerbations were reported in 0.6 and 3.7% of patients
The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients wit …
Feedback